Stoke Therapeutics (STOK) Other Non-Current Assets (2018 - 2026)
Stoke Therapeutics' quarterly Other Non-Current Assets came in at $3.2 million in Q1 2026, up 347.57% year-on-year from $721000.0 in Q1 2025, and up 1321.59% quarter-over-quarter from $227000.0 in Q4 2025.
Stoke Therapeutics has reported Other Non-Current Assets for 9 years, with the latest figure at $3.2 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 347.57% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 347.57% YoY), and the FY2025 full-year result was $227000.0, down 68.52% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.2 million, up from $227000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $3.2 million in Q1 2026, with the low at $227000.0 in Q4 2025.
- Average Other Non-Current Assets over 5 years is $732176.5, with a median of $569000.0 recorded in 2022.
- Year-over-year, Other Non-Current Assets soared 881.03% in 2022 and sank 68.52% in 2025.
- Tracing STOK's Other Non-Current Assets over 5 years: stood at $569000.0 in 2022, then changed by 0.0% to $569000.0 in 2023, then climbed by 26.71% to $721000.0 in 2024, then tumbled by 68.52% to $227000.0 in 2025, then soared by 1321.59% to $3.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $3.2 million (Q1 2026), $227000.0 (Q4 2025), and $721000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | 3.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.23 Mn |
| Dec 31, 2025 | 227,000.00 |
| Sep 30, 2025 | 721,000.00 |
| Jun 30, 2025 | 721,000.00 |
| Mar 31, 2025 | 721,000.00 |
| Dec 31, 2024 | 721,000.00 |
| Sep 30, 2024 | 494,000.00 |
| Jun 30, 2024 | 494,000.00 |
| Mar 31, 2024 | 569,000.00 |
| Dec 31, 2023 | 569,000.00 |
| Sep 30, 2023 | 569,000.00 |
| Jun 30, 2023 | 569,000.00 |
| Mar 31, 2023 | 569,000.00 |
| Dec 31, 2022 | 569,000.00 |
| Sep 30, 2022 | 569,000.00 |
| Jun 30, 2022 | 569,000.00 |
| Mar 31, 2022 | 569,000.00 |
| Dec 31, 2021 | 569,000.00 |
| Sep 30, 2021 | 569,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Mar 31, 2021 | 58,000.00 |
| Dec 31, 2020 | 205,000.00 |
| Sep 30, 2020 | 205,000.00 |
| Jun 30, 2020 | 205,000.00 |
| Mar 31, 2020 | 205,000.00 |
| Dec 31, 2019 | 205,000.00 |
| Sep 30, 2019 | 205,000.00 |
| Jun 30, 2019 | 205,000.00 |
| Dec 31, 2018 | 204,000.00 |